vs

Side-by-side financial comparison of Apyx Medical Corp (APYX) and USCB FINANCIAL HOLDINGS, INC. (USCB). Click either name above to swap in a different company.

USCB FINANCIAL HOLDINGS, INC. is the larger business by last-quarter revenue ($22.2M vs $19.2M, roughly 1.2× Apyx Medical Corp). USCB FINANCIAL HOLDINGS, INC. runs the higher net margin — 6.1% vs -6.8%, a 12.9% gap on every dollar of revenue. On growth, Apyx Medical Corp posted the faster year-over-year revenue change (34.7% vs 14.7%). USCB FINANCIAL HOLDINGS, INC. produced more free cash flow last quarter ($42.5M vs $-2.8M). Over the past eight quarters, Apyx Medical Corp's revenue compounded faster (36.8% CAGR vs 12.3%).

Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.

USCB Financial Holdings, Inc. is a U.S.-headquartered bank holding company that offers comprehensive retail and commercial banking services, including deposit products, personal and business loans, wealth management, and digital banking tools. It primarily serves individual consumers, small and medium-sized enterprises, and local corporate clients across its operating regions in the United States, prioritizing personalized customer experiences and community-oriented financial services.

APYX vs USCB — Head-to-Head

Bigger by revenue
USCB
USCB
1.2× larger
USCB
$22.2M
$19.2M
APYX
Growing faster (revenue YoY)
APYX
APYX
+20.0% gap
APYX
34.7%
14.7%
USCB
Higher net margin
USCB
USCB
12.9% more per $
USCB
6.1%
-6.8%
APYX
More free cash flow
USCB
USCB
$45.3M more FCF
USCB
$42.5M
$-2.8M
APYX
Faster 2-yr revenue CAGR
APYX
APYX
Annualised
APYX
36.8%
12.3%
USCB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
APYX
APYX
USCB
USCB
Revenue
$19.2M
$22.2M
Net Profit
$-1.3M
$1.4M
Gross Margin
62.6%
Operating Margin
0.1%
14.7%
Net Margin
-6.8%
6.1%
Revenue YoY
34.7%
14.7%
Net Profit YoY
71.9%
-80.3%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APYX
APYX
USCB
USCB
Q4 25
$19.2M
$22.2M
Q3 25
$12.9M
$25.0M
Q2 25
$11.4M
$24.4M
Q1 25
$9.4M
$22.8M
Q4 24
$14.2M
$23.0M
Q3 24
$11.5M
$21.5M
Q2 24
$12.1M
$20.5M
Q1 24
$10.2M
$17.6M
Net Profit
APYX
APYX
USCB
USCB
Q4 25
$-1.3M
$1.4M
Q3 25
$-2.0M
$8.9M
Q2 25
$-3.8M
$8.1M
Q1 25
$-4.2M
$7.7M
Q4 24
$-4.6M
$6.9M
Q3 24
$-4.7M
$6.9M
Q2 24
$-6.6M
$6.2M
Q1 24
$-7.6M
$4.6M
Gross Margin
APYX
APYX
USCB
USCB
Q4 25
62.6%
Q3 25
64.4%
Q2 25
62.3%
Q1 25
60.1%
Q4 24
63.0%
Q3 24
60.5%
Q2 24
61.7%
Q1 24
58.1%
Operating Margin
APYX
APYX
USCB
USCB
Q4 25
0.1%
14.7%
Q3 25
-6.5%
47.3%
Q2 25
-22.6%
44.0%
Q1 25
-32.4%
44.2%
Q4 24
-21.4%
39.6%
Q3 24
-31.6%
42.5%
Q2 24
-45.7%
39.8%
Q1 24
-64.6%
34.3%
Net Margin
APYX
APYX
USCB
USCB
Q4 25
-6.8%
6.1%
Q3 25
-15.4%
35.8%
Q2 25
-33.2%
33.4%
Q1 25
-44.0%
33.5%
Q4 24
-32.5%
30.0%
Q3 24
-40.9%
32.3%
Q2 24
-54.0%
30.3%
Q1 24
-74.0%
26.2%
EPS (diluted)
APYX
APYX
USCB
USCB
Q4 25
Q3 25
$0.45
Q2 25
Q1 25
Q4 24
Q3 24
$0.35
Q2 24
$-0.19
Q1 24
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APYX
APYX
USCB
USCB
Cash + ST InvestmentsLiquidity on hand
$31.7M
$38.5M
Total DebtLower is stronger
$37.5M
Stockholders' EquityBook value
$14.5M
$217.2M
Total Assets
$66.8M
$2.8B
Debt / EquityLower = less leverage
2.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APYX
APYX
USCB
USCB
Q4 25
$31.7M
$38.5M
Q3 25
$25.1M
$56.8M
Q2 25
$29.3M
$54.8M
Q1 25
$31.0M
$98.0M
Q4 24
$31.7M
$77.0M
Q3 24
$28.0M
$38.5M
Q2 24
$32.7M
$77.3M
Q1 24
$37.3M
$126.5M
Total Debt
APYX
APYX
USCB
USCB
Q4 25
$37.5M
Q3 25
$37.5M
Q2 25
$37.5M
Q1 25
$37.5M
Q4 24
$37.5M
Q3 24
$37.5M
Q2 24
Q1 24
Stockholders' Equity
APYX
APYX
USCB
USCB
Q4 25
$14.5M
$217.2M
Q3 25
$5.8M
$209.1M
Q2 25
$7.3M
$231.6M
Q1 25
$10.5M
$225.1M
Q4 24
$14.2M
$215.4M
Q3 24
$11.0M
$213.9M
Q2 24
$14.7M
$201.0M
Q1 24
$20.3M
$195.0M
Total Assets
APYX
APYX
USCB
USCB
Q4 25
$66.8M
$2.8B
Q3 25
$57.4M
$2.8B
Q2 25
$58.2M
$2.7B
Q1 25
$60.2M
$2.7B
Q4 24
$64.8M
$2.6B
Q3 24
$60.7M
$2.5B
Q2 24
$65.4M
$2.5B
Q1 24
$70.7M
$2.5B
Debt / Equity
APYX
APYX
USCB
USCB
Q4 25
2.58×
Q3 25
6.41×
Q2 25
5.17×
Q1 25
3.57×
Q4 24
2.64×
Q3 24
3.40×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APYX
APYX
USCB
USCB
Operating Cash FlowLast quarter
$-2.5M
$42.8M
Free Cash FlowOCF − Capex
$-2.8M
$42.5M
FCF MarginFCF / Revenue
-14.6%
191.4%
Capex IntensityCapex / Revenue
1.4%
1.4%
Cash ConversionOCF / Net Profit
31.40×
TTM Free Cash FlowTrailing 4 quarters
$-9.1M
$95.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APYX
APYX
USCB
USCB
Q4 25
$-2.5M
$42.8M
Q3 25
$-3.5M
$20.1M
Q2 25
$-1.2M
$18.0M
Q1 25
$-702.0K
$14.6M
Q4 24
$-2.9M
$34.8M
Q3 24
$-4.4M
$11.3M
Q2 24
$-4.3M
$18.3M
Q1 24
$-6.3M
$8.1M
Free Cash Flow
APYX
APYX
USCB
USCB
Q4 25
$-2.8M
$42.5M
Q3 25
$-4.1M
$20.0M
Q2 25
$-1.5M
$18.0M
Q1 25
$-757.0K
$14.6M
Q4 24
$-3.2M
$34.5M
Q3 24
$-4.6M
$11.2M
Q2 24
$-4.6M
$18.2M
Q1 24
$-6.4M
$8.0M
FCF Margin
APYX
APYX
USCB
USCB
Q4 25
-14.6%
191.4%
Q3 25
-31.5%
80.3%
Q2 25
-13.2%
73.7%
Q1 25
-8.0%
63.9%
Q4 24
-22.4%
150.2%
Q3 24
-40.0%
52.2%
Q2 24
-38.0%
88.8%
Q1 24
-62.2%
45.4%
Capex Intensity
APYX
APYX
USCB
USCB
Q4 25
1.4%
1.4%
Q3 25
4.0%
0.5%
Q2 25
2.3%
0.2%
Q1 25
0.6%
0.2%
Q4 24
1.7%
1.4%
Q3 24
1.3%
0.4%
Q2 24
2.4%
0.4%
Q1 24
0.3%
0.5%
Cash Conversion
APYX
APYX
USCB
USCB
Q4 25
31.40×
Q3 25
2.25×
Q2 25
2.22×
Q1 25
1.91×
Q4 24
5.05×
Q3 24
1.63×
Q2 24
2.95×
Q1 24
1.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons